A solution for activating or suppressing immune responses to any antigen.

  • Multi antigen and immunomodulator codelivery
  • Repeatable administration by any route
  • Fully synthetic, rapid manufacturing, reliable results

SNAPvax applications

SNAPvax tolerance vaccine (TV)

  • Autoantigens and immunomodulators codelivered to tolerogenic immune cells
  • Induces antigen-specific regulatory T cells providing a mild, potentially curative therapy for allergies & autoimmunity

SNAPvax cancer vaccine (CV)

  • Targeting of any tumor antigens (including PTMs) to induce anticancer T cells & antibodies
  • T cell priming + repeat administration by the intravenous route to engage every stage of the cancer immunity cycle for maximal benefit

SNAPvax antibody vaccine (AV)

  • Array of any minimal immunogen, including glycopeptides (not possible with RNA or viruses)
  • Focuses antibodies to conserved epitopes (minimal immunogens) thereby preventing escape and off-target toxicity


SNAPvax uses amphiphilic peptides that are chemically programmed to self-assemble into uniform nanoparticle compositions with any antigen and immunomodulator payloads.

Self-assembly ensures codelivery of antigens and immunomodulators in nanoparticles optimized for priming immune responses for fighting cancer, suppressing autoimmunity or preventing infection.


SNAPvax overcomes key limitations of conventional vaccine approaches.

Expression systems
(e.g., adenovirus, RNA)

Avidea's SNAPvax

Key challenges

  • Unable to target PTMs (e.g., glycopeptides)
  • Inherently pro-inflammatory (challenge for tolerance)
  • Immunomodulators limited to biologics
  • Anti-vector antibodies can prevent repeat administration
  • Narrow therapeutic index for IV administration
  • Recombinant, high mfg. costs, stability challenges with RNA


  • Can target any antigen (including PTMs)
  • Inert carrier enables programmable immune response
  • Capable of delivering key immunomodulators
  • Can be repeatedly administered to maintain immunity
  • IV administration (key for cancer treatment)
  • Fully synthetic, low-cost mfg., highly stable

Conventional nanoparticles
(e.g., liposome and PLGA particles)

Avidea's SNAPvax

Key challenges

  • Weakly immunogenic for inducing T cells
  • Variable drug loading, challenge for multi-antigen vaccines
  • Major mfg. challenges, including sterile filtration


  • Most efficient platform reported to-date for inducing T cells
  • Programmable, precise drug loading, no variability
  • Purpose-built to enable rapid and reliable vaccine manufacturing

Avidea's products are built on strong scientific principles

Scientific principles underlying technology platforms

In vivo characterization of the physicochemical properties of polymers-linked TLR agonists that enhance vaccine immunogenicity.

Read more

Description of SNAPvax as a platform for promoting T cell immunity

Peptide-TLR-7/8a conjugate vaccines chemically programmed for nanoparticle self-assembly enhance CD8 T-cell immunity to tumor antigens.

Read more

Immunological mechanisms for enhanced efficacy by intravenous vaccination

Intravenous nanoparticle vaccination generates stem-like TCF1+ neoantigen-specific CD8+ T cells.

Read more

Highly tunable and rapidly translatable

Modular platform allows facile hypothesis testing with myriad combinations of antigens, immunomodulators & targeting ligands


Proven design enables rapid manufacturing of vaccine candidates with high likelihood of success


Established cGMP processes, validated, rapid on-demand manufacturing